)
Zoetis (ZTS) investor relations material
Zoetis 46th Annual William Blair Growth Stock Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Business overview and market trends
Focus on advancing animal care through innovation, global scaling, and customer-centric delivery, with over $9.5 billion in annual revenue and 75+ years of expertise.
Broad portfolio spans diagnostics, medicines, vaccines, biodevices, and genetic testing, serving eight core species; companion animals account for 70% of business, livestock 30%.
Innovation pipeline includes 18 current blockbusters and potential for 12 more, targeting unmet needs in renal, oncology, cardiology, obesity, and anxiety.
Capital allocation prioritizes R&D and manufacturing investment, business development, and consistent shareholder returns via dividends and buybacks.
Macro environment and competitive landscape
Animal health market has historically grown 4%-6% annually, but recent quarters show consumer weakness, with pet owners delaying clinic visits and extending dosage intervals.
Adverse macro conditions and increased competition, especially in dermatology and parasiticides, are impacting demand and pricing.
U.S. clinic visits for pruritic conditions declined about 2% in the quarter; parasiticide share remains stable with sequential improvement.
Secular tailwinds like the human-animal bond and rising pet care engagement remain strong, supporting long-term growth.
Financial performance and outlook
Q1 results were impacted by the combination of competitive launches and inventory adjustments by distributors and retailers.
No significant improvement expected in macro conditions or competition intensity for the remainder of the year; easier year-over-year comparisons anticipated in the second half.
OA pain product Librela showed stabilization and modest sequential growth; easier comps expected to support higher growth rates in the back half.
- 2026 growth guided at 2%-5%, with innovation and targeted promotions offsetting competition.ZTS
Stifel Jaws & Paws Conference 202628 May 2026 - Solid growth, innovation focus, and recovery plans highlighted amid competitive pressures.ZTS
AGM 202622 May 2026 - Q1 2026 revenue up 3% to $2.3B, adjusted net income up 2% to $646M, guidance 2%–5% growth.ZTS
Q1 202613 May 2026 - Driving animal health innovation and growth with a diverse portfolio and global scale.ZTS
Corporate presentation8 Apr 2026 - 2026 proxy details strong growth, governance, and sustainability, with key votes on directors and pay.ZTS
Proxy filing8 Apr 2026 - Key votes include director elections, say-on-pay, auditor ratification, and written consent rights.ZTS
Proxy filing8 Apr 2026 - Growth in 2026 will be led by parasiticides, innovation in long-acting therapies, and expanding franchises.ZTS
2026 KeyBanc Capital Markets Healthcare Forum17 Mar 2026 - Triple combination parasiticides and livestock drive growth amid resilient global demand.ZTS
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - Strong product innovation and market expansion drive growth amid resilient pet health spending.ZTS
Leerink Global Healthcare Conference 20269 Mar 2026
Next Zoetis earnings date
Next Zoetis earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage